Bausch & Lomb and Alcon Laboratories, Inc. Settle Eye Vitamin Patent Dispute.ROCHESTER, N.Y. -- Bausch & Lomb (NYSE NYSE See: New York Stock Exchange :BOL BOL Bolivia (ISO Country code) BOL Books Online BOL Bole (SIL code, Nigeria) BOL Bill Of Lading BOL Beginning Of Line BOL Best Of Luck BOL Buzz Out Loud BOL Bruin Online BOL Beginning Of Life ) announces a settlement agreement ending a patent dispute relating to Alcon's ICAPS ICAPS Interactive Computer-Aided Provisioning System ICAPS Interactive Computer Aided Provisioning System ICAPS Internal Control Audit Planning Summary ICAPS Integrated Command Antisubmarine Warfare Prediction System ICAPS Integrated Carrier Acoustic/ASW Prediction System (R) AREDS AREDS Age-Related Eye Disease Study product. The agreement establishes a cross-licensing relationship that permits Alcon to continue to sell its AREDS-based nutraceutical product worldwide, and grants Bausch & Lomb global rights under one or more Alcon patents. The confidential terms of the agreement were approved by Bausch & Lomb's licensor, the United States Public Health Service United States Public Health Service (USPHS), n.pr a major division of the Department of Health and Human Services. The USPHS provides oversight of the following agencies: the Centers for Disease Control and Prevention (CDC); Food and Drug Administration . Bausch & Lomb filed a patent infringement lawsuit against Alcon in U.S. District Court in Rochester immediately after the U.S. Patent and Trademark Office granted a patent for the unique high-potency antioxidant and mineral formula in Bausch & Lomb's Ocuvite(R) PreserVision(TM), the only dietary supplement demonstrated to preserve eye health and vision in the National Eye Institute's landmark Age-Related Eye Disease Study The Age-Related Eye Disease Study was a clinical trial sponsored by the National Eye Institute, one of the National Institutes of Health in the United States. The study was designed to Bausch & Lomb, which co-developed the formula with the NEI and supplied the tablets used in the 10-year ARED ARED Ankara Profesyonel Turizm Rehberleri Dernegi (Turkey) study, holds the worldwide patent rights to the AREDS formula under a license agreement with the National Institutes of Health and the United States Public Health Service. Bausch & Lomb made the AREDS formulation available to consumers as Ocuvite PreserVision dietary supplements after the results of the ARED study were released in October 2001. Bausch & Lomb Ocuvite PreserVision is the No. 1 eye vitamin recommended by vitreoretinal specialists, and is the No. 1 product in the U.S. eye vitamin market, according to ACNielsen. Bausch & Lomb, with its Ocuvite line of ocular nutritional supplements, is the leader in U.S. eye vitamins. Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Founded in 1853, the Company is headquartered in Rochester, New York This article is about the city of Rochester in Monroe County. For the town in Ulster County, see Rochester, Ulster County, New York. Rochester, once known as The Flour City, and more recently as The Flower City or . Bausch & Lomb's 2004 revenues were $2.2 billion; it employs approximately 12,400 people worldwide and its products are available in more than 100 countries. More information about the Company can be found on the Bausch & Lomb Web site at www.bausch.com. Copyright Bausch & Lomb. Ocuvite and PreserVision are trademarks of Bausch & Lomb Incorporated. ICAPS is a trademark of Alcon, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion